• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Ataxia - Pipeline Review, H2 2012 Product Image

Ataxia - Pipeline Review, H2 2012

  • ID: 2335202
  • November 2012
  • 36 pages
  • Global Markets Direct

Ataxia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ataxia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ataxia. Ataxia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ataxia.
- A review of the Ataxia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Ataxia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Ataxia 7
Ataxia Therapeutics under Development by Companies 9
Ataxia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Ataxia Therapeutics – Products under Development by Companies 15
Ataxia Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Ataxia Therapeutics Development 17
NeuroSearch A/S 17
Shenzhen Beike Biotechnology Co., Ltd. 18
Ataxia – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
riluzole - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NSD-801 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cyclophosphamide + Prednisone + Gammaglobulin Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
dalfampridine ER - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Allogeneic Adult Adipose Derived Mesenchymal Stem Cells - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Ataxia Therapeutics - Dormant Products 33
Ataxia – Product Development Milestones 34
Featured News & Press Releases 34
Jul 30, 2012: EryDel Announces FDA Orphan Drug Designation For EryDex For Treatment Of Ataxia Telangiectasia 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products Under Development for Ataxia, H2 2012 7
Products under Development for Ataxia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
NeuroSearch A/S, H2 2012 17
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Ataxia Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Ataxia, H2 2012 7
Products under Development for Ataxia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos